Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Das M, Musetti S, Huang L. RNA interference-based cancer drugs: the roadblocks, and the "delivery" of the promise. Nucleic Acid Ther. 2019 Apr;29(2):61-6. doi: 10.1089/nat.2018.0762
Granero R, Fernandez-Aranda F, Aymami N, Gomez-Pena M, Fagundo AB, Sauchelli S, Del Pino-Gutierrez A, Moragas L, Savvidou LG, Islam MA, Tarrega S, Menchon JM, Jimenez-Murcia S. Subtypes of pathological gambling with concurrent illegal behaviors. J Gambl Stud. 2015 Dec;31(4):1161-78. doi: 10.1007/s10899-014-9499-5.
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.